GeoVax Initiates Outreach for Future Procurement of Mpox/Smallpox Vaccine

GeoVax Labs, a clinical-stage biotechnology company, has begun engaging with global health organizations to explore potential procurement of its GEO-MVA vaccine candidate for mpox and smallpox preparedness programs. The company believes that this outreach represents a strategic inflection point as GEO-MVA advances toward a pivotal Phase 3 study. Global preparedness programs for smallpox and mpox vaccines represent a potential multi-billion-dollar procurement market.